Abstract: There are provided a genomic DNA comprising 4 exons encoding the amino acid sequence as set forth in SEQ ID NO: 2 and 3 introns ligating them, and a splicing variant of said genomic DNA; as well as a DNA having the base sequence as set forth in SEQ ID NO: 4 and a promoter activity and the fragment thereof, and uses thereof.

Abstract: A method for isolating a gene encoding a membrane-bound protein characterized by fusing a functional protein with a fused protein itself, which differs from the existing TMT method in which an epitope recognized by an antibody is carried in a fused protein. This method enabled selective isolation of a gene encoding a membrane-bound protein.

Abstract: Modified antibodies containing 2 or more H chain V domains and or more L chain V domains of a monoclonal antibody which can transduce a signal into cells by crosslinking a cell surface molecule, thereby serving as an agonist. Because of being usable as agonists for signal transduction, these modified antibodies are useful as, for example, preventives and/or remedies for various diseases such as cancer, inflammation, hormone disorders and blood diseases.

Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking a cell surface molecule(s) to thereby serve as an agonist. The modified antibody can be used as a signal transduction agonist and, therefore, useful as a preventive and/or remedy for various diseases such as cancer, inflammation, hormone disorders and blood diseases.

Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a preventive and/or remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.

Abstract: Modified antibodies containing 2 or more H chain V domains and or more L chain V domains of a monoclonal antibody which can transduce a signal into cells by crosslinking a cell surface molecule, thereby serving as an agonist. Because of being usable as agonists for signal transduction, these modified antibodies are useful as, for example, preventives and/or remedies for various diseases such as cancer, inflammation, hormone disorders and blood diseases.

Abstract: A reshaped human anti-HM 1.24 antibody comprising: (A) an L chain comprising (1) the C region of a human L chain, and (2) the V region of an L chain comprising the FR of a human L chain and the CDR of the L chain of a mouse anti-HM 1.24 monoclonal antibody; and (B) an H chain comprising (1) the C region of a human H chain, and (2) the V region of an H chain comprising the FR of a human H chain and the CDR of the H chain of a mouse anti-HM 1.24 monoclonal antibody. Since most of this reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, the reshaped human antibody of the present invention has a low antigenicity and, therefore, is expected to be-used for medical treatment.

Abstract: There are provided a genomic DNA comprising 4 exons encoding the amino acid sequence as set forth in SEQ ID NO: 2 and 3 introns ligating them, and a splicing variant of said genomic DNA; as well as a DNA having the base sequence as set forth in SEQ ID NO: 4 and a promoter activity and the fragment thereof, and uses thereof.

Abstract: A method for isolating a gene encoding a membrane-bound protein characterized by fusing a functional protein with a fused protein itself, which differs from the existing TMT method in which an epitope recognized by an antibody is carried in a fused protein. This method enabled selective isolation of a gene encoding a membrane-bound protein.

Abstract: There are provided a genomic DNA comprising 4 exons encoding the amino acid sequence as set forth in SEQ ID NO: 2 and 3 introns ligating them, and a splicing variant of said genomic DNA; as well as a DNA having the base sequence as set forth in SEQ ID NO: 4 and a promoter activity and the fragment thereof, and uses thereof.

Abstract: A method for screening substances that inhibit binding between a TAK1 polypeptide and a TAB1 polypeptide, which comprises contacting the TAB1 polypeptide to the TAK1 polypeptide and a test sample and then detecting or determining the TAK1 polypeptide that is bound to the TAB1 polypeptide.

Abstract: A method and kit are provided for selectively isolating genes encoding membrane-bound proteins by fusing proteins to a secretable protein having a binding affinity to an antigen (e.g., an antibody), expressing these fusions in host cells, and selectively isolating individual host cells by their ability to bind the antigen via the fusion protein. Host cells expressing fusion proteins that do not contain a membrane binding domain will be relatively unable to bind the antigen, since the fusion proteins in those cells are secreted and unattached to their host cells. The method and kit disclosed herein are particularly useful for identifying genes for membrane-bound proteins represented in cDNA libraries.

Abstract: A DNA encoding a novel protein SMAP-1 having a signal sequence was successfully isolated by screening a cDNA library derived from human fetal hepatocyte using the TMT method developed originally by the inventors. Based on the expression pattern and structural properties, SMAP-1 was suggested to be a molecule playing an important role in living cells.

Abstract: A reshaped human anti-HM 1.

Abstract: A method for screening substances that inhibit binding between a TAK1 polypeptide and a TAB1 polypeptide, which comprises contacting the TAB1 polypeptide to the TAK1 polypeptide and a test sample and then detecting or determining the TAK1 polypeptide that is bound to the TAB1 polypeptide.

Abstract: A reshaped human anti-HM 1.

Abstract: The present invention discloses reshaped antibody to human medulloblastoma cells comprising:

Abstract: A method for screening substances that inhibit binding between a TAK1 polypeptide and a TAB1 polypeptide, which comprises contacting the TAB1 polypeptide to the TAK1 polypeptide and a test sample and then detecting or determining the TAK1 polypeptide that is bound to the TAB1 polypeptide.

Abstract: A method for screening substances that inhibit binding between a TAK1 polypeptide and a TAB1 polypeptide, which comprises contacting the TAB1 polypeptide to the TAK1 polypeptide and a test sample and then detecting or determining the TAK1 polypeptide that is bound to the TAB1 polypeptide.

Abstract: The present invention discloses reshaped antibody to human medulloblastoma cells comprising: (A) an L chain comprising: (1) a human L chain C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells; and, (B) an H chain containing: (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs and H chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells. Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as medulloblastoma which strongly express antigen that is recognized by this antibody.